However, ACE2 was undetectable in the nuclei of CD8+ T cells, suggesting that nuclear ACE2 may be specific to epithelial cell phenotypes in COVID-19, where it may be a useful therapeutic target. The gene discussed is CD8A; the disease is COVID-19.